Short description

aae-logo-pdfAeon Astron Europe BV is young and ambitious emerging company in biomedical devices and is dedicated to discovering, developing, producing and marketing high‐quality regenerative solutions to restore tissue damage. AAE offers regenerative solutions in ophthalmology, reconstructive and general surgery and dentistry. Particular focal point is R&D of biomaterial and regenerative medicine for ophthalmological applications. Aeon Astron Europe BV (AAE) was incorporated in February 2008 in Leiden, the Netherlands. AAE is a wholly owned subsidiary of Body Organ Biomedical Corporation (BOBC). BOBC was founded in 2007 and is headquartered in Taipei, Taiwan. AAE is dedicated to global sales and marketing for high value added and novel medical devices, as well as research and development of biomaterial and regenerative medicine for ophthalmological applications. These devices include ologen® Collagen Matrix, ologen™ BioCornea, and ologen™ BioLens, which are designed not only for eye tissue repair and vision improvement but also for improving the quality of life. AAE holds CE certificates, FDA‐510 K, and other registrations from many countries for ologen® Collagen Matrix and Aongen™. Presently (Q1 2015), AAE is organizing a “first in man” clinical trial at the Department of Ophthalmology, University of Cologne, to assess the safety and effectiveness of the ologen™ Biocornea to close the eye for a limited period of time of emergency patients with perforated corneal ulcerations/lacerations referred to the hospital for immediate treatment. Communication with the Competent Authority and Local Ethical Committee are in an advanced stage.

Main roles in the project

  • WP1: support all activities listed under WP1
  • WP3: leader of WP3, involved in tasks 3.1.1, 3.2.1, 3.2.2, 3.3.1, 3.3.2 and 3.3.
  • WP8: responsible as a leader of WP8, involved in all tasks

Key persons involved

Hans Schuitmaker (male) – PhD, Principal investigator

Dr Schuitmaker is Senior Scientist and Medical Liaison Officer at AAE. He has a Master degree in Biology, State University of Groningen, and a PhD in respiratory Physiology, Leiden University, The Netherlands. He has 30 years’ experience in biomedical and clinical research with a focus on photodynamic therapy in ophthalmology. Dr. Schuitmaker has over 5 years’ experience in pharmaceutical project management and more than 10 years’ experience in business development. He is the owner of several photodynamic treatment related patents and has >30 publications in peer reviewed international journals. Dr. Schuitmaker is an active Artillery reserve officer, present rank Lieutenant Colonel. For the ARREST BLINDNESS project Dr. Schuitmaker will be coordinating the clinical trial(s) at AAE/BOBC and he will also be involved in the general coordination and communication between AAE and the ARREST BLINDNESS consortium.

Kenn Curt Daniel (male) – PhD, Deputy principal investigator

Dr K.C. Daniel, is Chief Operating Officer at AAE. He has a Master’s degrees in both Biology and Chemistry of the Leiden University and a PhD in Medicine from King College London School of Medicine and Dentistry. He has over 20 years’ experience in the biomedical industry in various positions from bench to office, including Equity Analyst Biotechnology at a major bank and Business Development in academia. In his current role as Chief Operating Officer at AAE he has extensive hands-on International Sales and Marketing experience with responsibilities of Europe, Middle East, Africa, North America (USA, Canada and Mexico) and Latin America (including Brazil).

Michael Lai (male) – Chief Executive Officer at AAE, the Netherlands, and Body Organ Biomedical Corporation, Taiwan

Michael has more than 20 years experience in medical sales and marketing. He is the President and the General Manager of Aeon Astron Europe B.V. and Body Organ Biomedical Corporation. Michael is widely experienced and interested in medical and biotechnology-based business development, regulation and marketing.





Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.